Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion
·1 min
Pharmaceutical giant Johnson & Johnson has announced its plans to acquire Ambrx Biopharma, a leading developer of cancer treatments, in a cash deal worth $2 billion. This acquisition aligns with Johnson & Johnson’s ongoing efforts to expand its presence in the oncology market and enhance its portfolio of innovative therapies. The deal is expected to bolster Johnson & Johnson’s research and development capabilities in the cancer treatment space.